高密度脂蛋白与肾脏疾病
HDL and Kidney Diseases.
机构信息
The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
出版信息
Adv Exp Med Biol. 2022;1377:163-170. doi: 10.1007/978-981-19-1592-5_13.
Serum lipid profiles, as well as HDL can be altered in patients with kidney diseases. There are various types of kidney diseases, including nephrotic syndrome and chronic kidney disease. In patients with nephrotic syndrome, plasma levels of HDL cholesterol and ApoA-I were within or below the normal limits. The HDL cholesterol: total cholesterol ratio decreased compared to healthy individuals. In patients with chronic kidney disease (CKD), reverse cholesterol transport function of HDL is impaired, and CKD also affects the composition and function of HDL. Cardiovascular disease (CVD) is the severe complication of CKD. Furthermore, HDL might also be a potential target for the prevention of cardiovascular complications associated with CKD.
血清脂质谱，以及高密度脂蛋白（HDL），在肾脏疾病患者中可能会发生改变。肾脏疾病有多种类型，包括肾病综合征和慢性肾脏病。在肾病综合征患者中，血浆 HDL 胆固醇和载脂蛋白 A-I 水平处于或低于正常范围。与健康个体相比，HDL 胆固醇：总胆固醇比值降低。在慢性肾脏病（CKD）患者中，HDL 的胆固醇逆向转运功能受损，CKD 还会影响 HDL 的组成和功能。心血管疾病（CVD）是 CKD 的严重并发症。此外，HDL 也可能是预防与 CKD 相关的心血管并发症的潜在靶点。
Zotero 插件